Laparoscopic versus Open Splenectomy and Devascularization for Massive Splenomegaly Due to Portal Hypertension

Although the clinical benefit of laparoscopic splenectomy and devascularization（LSD） has been elaborated in many studies,its application in massive splenomegaly remains controversial.We conducted a retrospective research to assess the curative efficacy of LSD for massive splenomegaly due to portal hypertension.Forty-seven patients with massive splenomegaly due to portal hypertension were enrolled in this study,and divided into two groups.Twenty-one patients underwent open splenectomy and devascularization（OSD） from June 2010 to October 2012（OSD group）.From March 2013 to February 2015,LSD was performed on 26 patients（LSD group）.Perioperative variables were analyzed.Compared to OSD,LSD was associated with less blood loss（241.9±110.0 m L vs.319.0±139.5 m L,P〈0.05）,more rapid resumption of oral diet（2.46±0.95 days vs.3.76±1.09 days,P〈0.05）,and shorter postoperative hospital stay（5.35±1.65 days vs.7.24±1.55 days,P〈0.05）.It was concluded that for patients with massive splenomegaly due to portal hypertension,LSD is feasible and as safe as OSD.

Prevention and Treatment of Hemorrhage during Laparoscopic Splenectomy and Devascularization for Portal Hypertension

This study was aimed to explore prevention and treatment of hemorrhage during laparoscopic splenectomy plus devascularization（LSD） for portal hypertension by modified and simplified operation. From June 2012 to June 2014, LSD was performed on 138 patients with portal hypertension. The patients were allocated into two groups： earlier stage（ES） group, in which 45 patients received traditional LSD from June 2012 to Sep. 2012; later stage（LS） group, in which 93 patients underwent modified LSD from Jan. 2013 to June 2014. Perioperative variables were compared between the two groups. Laparoscopic operations were successfully performed in all but two patients in ES group who were converted to laparotomy（total conversion rate： 1.4%）. There was no perioperative death or reoperation, and all patients recovered and were discharged from hospital with no serious complications in the six months of postoperative follow-up. The average time in the ES group was longer than that in the LS group（335.1 min vs. 201.3 min, P〈0.05）. LS group outperformed ES group in terms of blood loss（705.4 m L vs. 910.4 mL, P〈0.05）. The average operation time to oral diet intake after surgery（40.5 h vs. 50.3 h, P〈0.05） and postoperative hospital stay（7.4 d vs. 9.0 days, P〈0.05） were much less in the LS group than in the ES group. The overall complication rate（4.3 % vs. 11.1 %, P〈0.05） and conversion rate（0% vs. 4.4%, P〈0.05） were lower in the LS group than in the ES group. It was concluded that prevention and treatment of hemorrhage are the key points of LSD for portal hypertension. By creating a tunnel above the splenic pedicle and a tunnel behind the lower esophagus, the simplified and modified LSD can reduce hemorrhage and improve success of surgery dramatically, and splenomegaly and severe varices are not contraindications.

Transjugular intrahepatic portosystemic shunt versus open splenectomy and esophagogastric devascularization for portal hypertension with recurrent variceal bleeding

BACKGROUND： Transjugular intrahepatic portosystemic shunt（TIPS） and open splenectomy and esophagogastric devascularization（OSED） are widely used to treat patients with portal hypertension and recurrent variceal bleeding（PHRVB）. This study aimed to compare the effectiveness between TIPS and OSED for the treatment of PHRVB.METHODS： The data were retrospectively retrieved from 479 cirrhotic patients（Child-Pugh A or B class） with PHRVB, who had undergone TIPS（TIPS group） or OSED（OSED group） between January 1, 2010 and October 31, 2014.RESULTS： A total of 196 patients received TIPS, whereas 283 underwent OSED. Within one month after TIPS and OSED, the rebleeding rates were 6.1% and 3.2%, respectively（P=0.122）. Significantly lower incidence of pleural effusion,splenic vein thrombosis, and pulmonary infection, as well as higher hepatic encephalopathy rate, shorter postoperative length of hospital stay, and higher hospital costs were observed in the TIPS group than those in the OSED group. During the follow-up periods（29 months）, significantly higher incidences of rebleeding（15.3% vs 4.6%, P=0.001） and hepatic encephalopathy（17.3% vs 3.9%, P=0.001） were observed in the TIPS group than in the OSED group. The incidence of instent stenosis was 18.9%. The survival rates were 91.3% in the TIPS group and 95.1% in the OSED group. The long-term liver function did not worsen after either TIPS or OSED.CONCLUSION： For the patients with liver function in the Child-Pugh A or B class, TIPS is not superior over OSED in terms of PHRVB treatment and rebleeding prevention.

Esophagogastric devascularization without splenectomy in portal hypertension: safe and effective?

BACKGROUND： Esophagogastric variceal hemorrhage is a life-threatening complication of portal hypertension. In this study, we compared the therapeutic effect of a novel surgi- cal procedure, esophagogastric devascularization without splenectomy （EDWS）, with the widely used modified esopha- gogastric devascularization （MED） with splenectomy for the treatment of portal hypertension.

Combined splenocaval or mesocaval C shunt and portoazygous devascularization in the treatment of portal hypertension: analysis of 150 cases

BACKGROUND: Portal hypertension is a common disease and its major surgical therapeutic approaches include devascularization and shunting. This study was undertaken to investigate the effects of combined splenocaval or mesocaval C shunt and portoazygous devascularization (combined procedures) on portal hypertension. METHODS: The clinical data of 150 patients with portal hypertension who had undergone combined procedures at the First Affiliated Hospital of Zhengzhou University from May1990 to May 2003 were analyzed retrospectively. RESULTS: The mean free portal pressure (FPP) was 25.6±1.83 mmHg, 18.0±2.07 mmHg and 18.4±2.19 mmHg before operation, after splenectomy plus splenocaval or mesocaval C shunt, and combined procedures, respectively. There was no operative death in all patients. The 1-7 year follow-up of 100 patients showed rebleeding in 3 patients, encephalopathy in 4, thrombosis of artificial vascular graft in 3, and dying from liver failure in 2. CONCLUSIONS: The combined procedures can not only decrease portal pressure but also preserve hepatic blood flow to some extent. It may be one of the best choices for treating portal hypertension in China.

Combined Laparoscopic Splenectomy and Esophagogastric Devascularization versus Open Splenectomy and Esophagogastric Devascularization for Portal Hypertension due to Liver Cirrhosis

This study was conducted to compare the feasibility,safety and effectiveness of the combined-laparoscopic splenectomy and esophagogastric devascularization(C-LSED)with open splenectomy and esophagogastric devascularization surgery(OSED)in patients with portal hypertension due to liver cirrhosis.From February 2014 to June 2018,68 patients with portal hypertension were diagnosed as having serious gastroesophageal varices and/or hypersplenism in our center.Thirty patients underwent C-LSED and 38 patients received OSED.Results and outcomes were compared retrospectively.No patients of C-LSED group required an intraoperative conversion to open surgery.Significantly shorter operating time,less blood loss,lower transfusion rates,shorter postoperative hospital stay,lower rates of complications were found in C-LSED group than in C-LSED group(P<0.05).No death and rebleeding were documented in both groups during the follow-up periods of one year Postoperative endoscopy revealed that varices in the patients of both groups were alleviated significantly from severe to mild,and in a part of cases,the varices disappeared.The final results suggest that the C-LSED technique is superior to open procedure,due to slightly invasive,simplified operative procedure,significantly shorter operating time,less intraoperative bleeding and lower post-operative complication rates.And C-LSED offers comparable long-term effects to open surgery.

Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization

AIM:To compare the incidence of early portal or splenic vein thrombosis(PSVT) in patients treated with irregular and regular anticoagulantion after splenectomy with gastroesophageal devascularization.METHODS:We retrospectively analyzed 301 patients who underwent splenectomy with gastroesophageal devascularization for portal hypertension due to cirrhosis between April 2004 and July 2010.Patients were categorized into group A with irregular anticoagulation and group B with regular anticoagulation,respectively.Group A(153 patients) received anticoagulant monotherapy for an undesignated time period or with aspirin or warfarin without low-molecular-weight heparin(LMWH) irregularly.Group B(148 patients) received subcutaneous injection of LMWH routinely within the first 5 d after surgery,followed by oral warfarin and aspirin for one month regularly.The target prothrombin time/international normalized ratio(PT/INR) was 1.25-1.50.Platelet and PT/INR were monitored.Color Doppler imaging was performed to monitor PSVT as well as the effectiveness of thrombolytic therapy.RESULTS:The patients' data were collected and analyzed retrospectively.Among the patients,94 developed early postoperative mural PSVT,including 63 patients in group A(63/153,41.17%) and 31 patients in group B(31/148,20.94%).There were 50(32.67%) patients in group A and 27(18.24%) in group B with mural PSVT in the main trunk of portal vein.After the administration of thrombolytic,anticoagulant and antiaggregation therapy,complete or partial thrombus dissolution achieved in 50(79.37%) in group A and 26(83.87%) in group B.CONCLUSION:Regular anticoagulation therapy can reduce the incidence of PSVT in patients who undergo splenectomy with gastroesophageal devascularization,and regular anticoagulant therapy is safer and more effective than irregular anticoagulant therapy.Early and timely thrombolytic therapy is imperative and feasible for the prevention of PSVT.

A Prospective Randomized Trial of Selective versus Nonselective Esophagogastric Devascularization for Portal Hypertension

Cirrhosis with portal hypertension is a common disease which has a significant impact on the quality of patients＇ life. Esophagogastric devascularization（EGDV） has been demonstrated to be an effective method to treat portal hypertension, however certain complications are associated with it. The purpose of this study was to evaluate the effectiveness and clinical outcome of the selective EGDV（sEGDV） for the treatment of portal hypertension. The study was conducted prospectively from Jan. 1 2011 to Dec. 31, 2012, and 180 patients were randomized to the sEGDV group（n=90） or the non-sEGDV（n-sEGDV） group（n=90）. Patients＇ demographics, preoperative lab test results and operative details were comparable between the two groups. Postoperative and short-term complications were analyzed in two groups. There was statistically significant difference（P〈0.01） in the PVF reduction between the two groups. Post-operative complications showed no statistically significant difference between the two groups in the incidence of bleeding, ascites, acute portal vein thrombosis, fever and hepatic encephalopathy. Mortality between two groups was comparable. The incidence of splenic fossa effusion after the surgery was lower in sEGDV group than in n-sEGDV group. There were no significant differences in the short-term follow-up data such as esophageal varices and portal hypertensive gastropathy（P〉0.05）. It is suggested that sEGDV is a safe, simple and effective surgical procedure. It has both the advantages of the shunt and devascularization because it preserves body＇s voluntary diversion. With the advantage of low incidence of postoperative complications, it is an ideal surgical approach for the treatment of portal hypertension.

Indocyanine green retention is a potential prognostic indicator after splenectomy and pericardial devascularization for cirrhotic patients

BACKGROUND：Splenectomy and pericardial devascularization（SPD）is an effective treatment of upper gastrointestinal bleeding and hypersplenism in cirrhotic patients with portal hypertension.Indocyanine green retention at 15 minutes（ICGR15）was reported to offer better sensitivity and specificity than the Child-Pugh classification in hepatectomy,but few reports describe ICGR15 in SPD.The present study was to evaluate the prognostic value of ICGR15 for cirrhotic patients with portal hypertension who underwent SPD.METHODS：From January 2012 to January 2015,43 patients with portal hypertension and hypersplenism caused by liver cirrhosis were admitted in our center and received SPD.The ICGR15,Child-Pugh classification,model for end-stage liver disease（MELD）score,and perioperative characteristics were analyzed retrospectively.RESULTS：Preoperative liver function assessment revealed that 34 patients were Child-Pugh class A with ICGR15 of13.6%-43.0%and MELD score of 7-20;8 patients were class B with ICGR15 of 22.8%-40.7%and MELD score of 7-17;1patient was class C with ICGR15 of 39.7%and MELD score of 22.The optimal ICGR15 threshold for liver function compensation was 31.2%,which offered a sensitivity of 68.4%and a specificity of 70.8%.Univariate analysis showed preoperative ICGR15,MELD score,surgical procedure,intraoperative blood loss,and autologous blood transfusion were significantly different between postoperative liver function compensated and decompensated groups.Multivariate regression analysis revealed that ICGR15 was an independent risk factor of postoperative liver function recovery（P=0.020）.CONCLUSIONS：ICGR15 has outperformed the Child-Pugh classification for assessing liver function in cirrhotic patients with portal hypertension.ICGR15 may be a suitable prognostic indicator for cirrhotic patients after SPD.

Evaluation of the effects of combined endoscopic variceal ligation and splenectomy with pericardial devascularization on esophageal varices

AIM: To detect the hemodynamic alterations in collateral circulation before and after combined endoscopic variceal ligation (EVL) and splenectomy with pericardial devascularization by ultrasonography, and to evaluate their effect using hemodynamic parameters. METHODS: Forty-three patients with esophageal varices received combined EVL and splenectomy with pericardial devascularization for variceal eradication. The esophageal vein structures and azygos blood flow (AZBF) were detected by endoscopic ultrasonography and color Doppler ultrasound. The recurrence and rebleeding of esophageal varices were followed up. RESULTS: Patients with moderate or severe varices in the esophageal wall and those with severe peri- esophageal collateral vein varices had improvements after treatment, while the percentage of patients with severe para-esophageal collateral vein varices decreased from 54.49% to 2.33%, and the percentage of patients with detectable perforating veins decreased from 79.07% to 4.65% (P < 0.01). Color Doppler flowmetry showed a significant decrease both in AZBF (43.00%, P < 0.05) and in diameter of the azygos vein (28.85%, P < 0.05), while the blood flow rate was unchanged. The recurrence rate of esophageal varices was 2.5% (1/40, mild), while no re-bleeding cases were recorded. CONCLUSION: EVL in combination with splenectomy with pericardial devascularization can block the collateral veins both inside and outside of the esophageal wall, and is more advantagious over splenectomy in combination with pericardial devascularization or EVL in preventing recurrence and re-bleeding of varices.

In situ subtotal spleen resection combined with selective pericardial devascularization for the treatment of portal hypertension

BACKGROUND Hypersplenism and esophageal varices bleeding are the major complications of portal hypertension(PHT).In recent years,increasing attention has been given to spleen preservation operations.The mode and long-term effects of subtotal splenectomy and selective pericardial devascularization for PHT remain controversial.AIM To investigate the clinical efficacy and safety of subtotal splenectomy combined with selective pericardial devascularization for the treatment of PHT.METHODS This was a retrospective study of 15 patients with PHT who underwent subtotal splenectomy not preserving the splenic artery or vein combined with selective pericardial devascularization in the Department of Hepatobiliary Surgery,Qilu Hospital of Shandong University from February 2011 to April 2022.Fifteen propensity score-matched patients with PHT who underwent total splenectomy at the same time served as the control group.The patients were followed for up to 11 years after surgery.We compared the postoperative platelet levels,perioperative splenic vein thrombosis,and serum immunoglobulin levels between the two groups.Abdominal enhanced computed tomography was used to evaluate the blood supply and function of the residual spleen.The operation time,intraoperative blood loss,evacuation time,and hospital stay were compared between the two groups.RESULTS The postoperative platelet level of patients in the subtotal splenectomy group was significantly lower than that in the total splenectomy group(P<0.05),and the postoperative portal system thrombosis rate in the subtotal splenectomy group was also much lower than that in the total splenectomy group.The levels of serum immunoglobulins(IgG,IgA,and IgM)showed no significant differences after surgery compared with before surgery in the subtotal splenectomy group(P>0.05),but serum immunoglobulin IgG and IgM levels decreased dramatically after total splenectomy(P<0.05).The operation time in the subtotal splenectomy group was longer than that in the total splenectomy group(P<0.05),but there were no significant differences in the amount of intraoperative blood loss,evacuation time,or hospital stay between the two groups.CONCLUSION Subtotal splenectomy not preserving the splenic artery or vein combined with selective pericardial devascularization is a safe and effective surgical treatment for patients with PHT,not only correcting hypersplenism but also preserving splenic function,especially immunological function.

Prognosis after splenectomy plus pericardial devascularization vs transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding

BACKGROUND Portal hypertension combined with esophagogastric variceal bleeding(EGVB)is a serious complication in patients with hepatitis B virus(HBV)-related cirrhosis in China.Splenectomy plus pericardial devascularization(SPD)and transjugular intrahepatic portosystemic shunt(TIPS)are effective treatments for EGVB.However,a comparison of the effectiveness and safety of those methods is lacking.AIM To compare the prognosis after SPD vs TIPS for acute EGVB after failure of endoscopic therapy or secondary prophylaxis of variceal rebleeding(VRB)in patients with HBV-related cirrhosis combined with portal hypertension.METHODS This retrospective cohort study included 318 patients with HBV-related cirrhosis and EGVB who underwent SPD or TIPS at West China Hospital of Sichuan University during 2009-2013.Propensity score-matched analysis(PSM),the Kaplan-Meier method,and multivariate Cox regression analysis were used to compare overall survival,VRB rate,liver function abnormality rate,and hepatocellular carcinoma(HCC)incidence between the two patient groups.RESULTS The median age was 45.0 years(n=318;226(71.1%)males).During a median follow-up duration of 43.0 mo,18(11.1%)and 33(21.2%)patients died in the SPD and TIPS groups,respectively.After PSM,SPD was significantly associated with better overall survival(OS)(P=0.01),lower rates of abnormal liver function(P<0.001),and a lower incidence of HCC(P=0.02)than TIPS.The VRB rate did not differ significantly between the two groups(P=0.09).CONCLUSION Compared with TIPS,SPD is associated with higher postoperative OS rates,lower rates of abnormal liver function and HCC,and better quality of survival as acute EGVB treatment after failed endoscopic therapy or as secondary prophylaxis of VRB in patients with HBV-related cirrhosis combined with portal hypertension.There is no significant between-group difference in VRB rates.

失效模式与效应分析在食管胃底静脉曲张内镜下食管胃底静脉曲张精准断流术后患者中的应用效果

目的探究失效模式与效应分析在食管胃底静脉曲张内镜下食管胃底静脉曲张精准断流术(ESVD)后患者中的应用效果。方法选取2022年1月至11月九江学院附属医院收治的101例食管胃底静脉曲张ESVD后患者作为研究对象,采用随机数字表法分为对照组(50例)和观察组(51例)。对照组进行常规护理干预,观察组进行失效模式与效应分析为指导的护理干预。比较两组的住院时间、并发症发生率、满意度、护理干预前后的疼痛情况[数字评价量表(NRS)]及情绪状态[焦虑自评量表(SAS)及抑郁自评量表(SDS)]。结果观察组的住院时间短于对照组,并发症总发生率低于对照组,满意度高于对照组,差异有统计学意义(P<0.05);两组护理干预前的NRS评分、SAS评分及SDS评分比较,差异无统计学意义(P>0.05),观察组护理干预1、3、5 d的NRS评分、SAS评分及SDS评分低于对照组,差异有统计学意义(P<0.05)。结论失效模式与效应分析在食管胃底静脉曲张ESVD后患者中的应用效果较好,可缩短患者的住院时间及降低并发症发生率,同时对患者的疼痛及不良情绪也有较好的改善作用,更受患者认可。

Successful endoscopic treatment of superficial esophageal cancer in a patient with esophageal variceal bleeding:A case report

BACKGROUND The coexistence of esophageal variceal bleeding and superficial esophageal cancer(SEC)is relatively rare in clinical practice.Moreover,there have been few reports of SEC overlying esophageal varices(EVs).Herein,we report our successful use of endoscopic submucosal dissection(ESD),esophageal solitary venous dilatation(ESVD),and endoscopic injection sclerotherapy(EIS)to treat a 75-year-old man who was diagnosed with SEC coexisting with esophageal variceal bleeding.CASE SUMMARY A 75-year-old man was admitted to the hospital due to black stool for 4 days.The patient had a history of liver cancer,cirrhosis,and portal hypertension.Endosco-pic examination revealed esophageal and gastric varicose veins,as well as esoph-ageal carcinoma in situ.We first treated esophageal variceal bleeding by ESVD and EIS.One week later,ESD treatment was done,and the complete rese-ction of early esophageal cancer was successfully completed via endoscopy.There were no postoperative complications,such as bleeding,infection,or perforation.CONCLUSION The sequential treatment of ESVD,EIS,and ESD is an effective method for trea-ting EVs with early esophageal cancer.

腹腔镜脾切除联合贲门周围血管离断术治疗门静脉高压症的临床价值评估

目的:评估腹腔镜脾切除联合贲门周围血管离断术的优越性、安全性,以期为门静脉高压症手术治疗方案的选择提供依据。方法:回顾分析2017年3月至2021年11月收治的215例门静脉高压症患者的临床资料,其中研究组(n=68)行腹腔镜脾切除联合贲门周围血管离断术,从行开腹脾切除联合贲门周围血管离断术的患者中抽取68例作为对照组,比较两组围手术期相关指标、术后并发症等。结果:研究组手术时间长于对照组,术中出血量、术后住院时间、腹腔引流管留置时间、术后并发症均少于对照组,差异有统计学意义(P<0.05);两组术中自体血回输量差异无统计学意义(P>0.05)。结论:腹腔镜脾切除联合贲门周围血管离断术安全、效果显著,与传统开腹脾切除联合贲门周围血管离断术相比,具有创伤更小、术中容易暴露解剖间隙、康复快、住院时间短、并发症少的优点,值得推广应用。

腹腔镜辅助改良Sugiura手术与脾切除断流术对肝硬化门静脉高压症患者肝纤维化和凝血功能及再出血率的影响

目的探讨腹腔镜辅助改良Sugiura手术与脾切除断流术对肝硬化门静脉高压症(PHT)患者肝纤维化、凝血功能及再出血率的影响。方法选取2021年1月至2022年6月监利市第五人民医院收治的85例肝硬化PHT患者作为研究对象,根据手术方式不同分为断流组(n=39)与改良组(n=46)。断流组给予脾切除断流术治疗,改良组给予改良Sugiura手术治疗,比较两组手术情况及住院时间、门静脉血流动力学指标、肝纤维化指标、并发症发生情况及再出血率。结果两组手术时间、术中出血量及住院时间比较差异无统计学意义。术后,两组门静脉内径(Dpv)均短于术前,门静脉血流速度(Vpv)、门静脉血流量(Qpv)均慢于术前,且改良组Dpv短于断流组,Vpv、Qpv均慢于断流组,差异有统计学意义(P<0.05)。术后,两组透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)水平均低于术前,且改良组低于断流组,差异有统计学意义(P<0.05)。术后,两组纤维蛋白原(Fg)水平均高于术前,凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)均短于术前,且改良组Fg水平高于断流组,PT、APTT均短于断流组,差异有统计学意义(P<0.05)。改良组并发症发生率、再出血率均低于断流组,差异有统计学意义(P<0.05)。结论与脾切除断流术相比,腹腔镜辅助改良Sugiura手术治疗肝硬化PHT治疗效果更佳,可显著改善患者肝功能,延缓肝纤维化进程,降低再出血率,安全性较佳。

腹腔镜脾动脉结扎联合贲门周围血管离断术治疗肝硬化门静脉高压症的回顾性研究

目的探讨腹腔镜脾动脉结扎(SAL)联合贲门周围血管离断术(EED)治疗肝硬化门静脉高压症(PHT)的治疗效果。方法回顾性研究2020年7月至2023年5月安阳市第三人民医院和安阳市第五人民医院收治的126例肝硬化PHT患者资料,根据不同手术方式分为观察组(69例,行腹腔镜SAL术联合EED)和对照组[57例,行腹腔镜脾切除术(LS)联合EED]。比较两组患者围术期指标;比较术前及术后14 d血常规指标[血小板计数(PLT)、白细胞计数(WBC)、红细胞计数(RBC)]、肝功能指标[丙谷转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(GGT)]、凝血功能指标[活化部分凝血酶时间(APTT)、纤维蛋白原(FIB)、凝血原酶时间(PT)],观察两组患者术后并发症发生情况。结果观察组各项围术期指标均低于对照组(P<0.05);术后14 d,观察组PLT、WBC水平低于对照组(P<0.05),且RBC水平与对照组比较差异无统计学意义(P>0.05);观察组ALT、AST、GGT、APTT、PT水平低于对照组,FIB高于对照组(P<0.05);观察组术后并发症总发生率低于对照组(P<0.05)。结论腹腔镜SAL联合EED能提高治疗肝硬化PHT的手术效果,改善患者脾功能亢进,改善肝功能及凝血功能,降低并发症的发生。

腹腔镜脾切除(附20例报告)

目的探讨腹腔镜脾切除及腹腔镜脾切除联合断流手术的方法、临床效果及优缺点。方法回顾性分析20例腹腔镜脾切除手术病例(包括6例腹腔镜下脾切除联合断流手术)的临床资料。结果20例病人中有1例中转开腹,19例均顺利完成腹腔镜脾切除术或腹腔镜脾切除联合断流手术,13例腹腔镜脾切除平均手术165.0min,术中平均失血87mL,术后平均禁食1.5d,术后平均住院6d。6例腹腔镜脾切除联合断流手术平均手术268min,术中平均失血800mL,手术后禁食2.5d,手术后平均住院8d。结论腹腔镜脾切除及腹腔镜脾切除联合断流手术是安全且效果良好的手术,手术成功的关键是术中仔细操作,控制脾蒂,防止大出血。

选择性与非选择性贲门周围血管离断术治疗门静脉高压症的临床研究

目的:对比分析选择性与非选择性贲门周围血管离断术治疗门静脉高压症的临床疗效。方法:回顾性分析我院2004-2008年因门静脉高压症实施选择性贲门周围血管离断术患者57例(选择组)和贲门周围血管离断术患者51例(非选择组)的临床资料,通过彩色多普勒超声测定手术前后门静脉与肝动脉血流量变化,并术中监测自由门静脉压力(FPP)。结果:断流术后选择组FPP较非选择组FPP下降幅度更大,差异有统计学意义(P<0.05);断流术后1个月两组患者门静脉血流量均减少,选择组减少更多,差异有统计学意义(P<0.001);断流术后1个月两组肝动脉血流量均增加,选择组增加更多,差异有统计学意义(P<0.001)。选择组近期并发症发生率为15.8%,非选择组为27.5%(P<0.05)。选择组50例完成6～36个月随访,复发出血率为16.0%,3年生存率88%;非选择组42例完成6～36个月随访,复发出血率为30.2%,3年生存率78.6%。结论:选择性贲门周围血管离断术治疗门静脉高压症的临床疗效优于非选择性贲门周围血管离断术。

脾切除断流术后经脾静脉抗凝治疗预防早期门静脉血栓的安全性分析

目的评价经脾静脉置管抗凝治疗预防脾切除断流术后早期门静脉血栓(PVT)形成的安全性。方法 60例择期行脾切除断流术的门脉高压患者随机分为置管组和对照组,采用超声多普勒和(或)强化螺旋CT扫描监测术后门静脉血栓形成情况。结果 60例患者全部随访到3个月。对照组累计PVT发生率56.7%,置管组为16.7%,两组有统计学差异(P<0.05)。经脾静脉置管输入肝素溶液对体循环静脉血凝血酶原时间和活化部分凝血活酶时间无影响。结论经脾静脉置管抗凝治疗预防脾切除断流术后早期门静脉血栓形成是安全可行的。